Physician profile
Ruchi Sood
NPI 1700191343
$1,776.21
in general payments reported to CMS, 2019-2025
20 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $16.17 · 2021: $99.33 · 2022: $166 · 2023: $253 · 2024: $468 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Education: $40.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.92 |
| Education | $40.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $282.97 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $207.96 | 2024-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $192.56 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $189.54 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $188.91 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $119.75 | 2024-2025 | |
| Akebia Therapeutics INC | $114.53 | 2021-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $96.70 | 2023-2025 | Jynarque |
| Ardelyx, INC. | $85.74 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $74.90 | 2022-2023 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.73 | 2023-2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $33.22 | 2024 | Crysvita |
| Vifor Pharma, INC. | $26.35 | 2022 | |
| Travere Therapeutics, INC. | $22.53 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.33 | 2024 | Keveyis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $18.66 | 2025 | |
| Cormedix INC. | $18.44 | 2024 | Defencath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.17 | 2020 | |
| Novo Nordisk INC | $14.87 | 2025 | Ozempic |
| Horizon Therapeutics Plc | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.